Virginia Tech Carilion Research Institute

Virginia Tech Carilion Research Institute is presented as a base for research aimed at closing the gap between opioid-overdose emergencies and continuing treatment. Its role comes into focus through Warren Bickel’s grant-funded pilot to connect patients directly from emergency care to outpatient buprenorphine, an intervention shaped by evidence but developed amid a region-wide shortage of timely treatment.

Research and the proposed pilot

Warren Bickel had secured a $1 million grant for Virginia Tech Carilion Research Institute to pilot new medication-assisted treatment protocols. The project’s practical aim was to streamline the transfer from an emergency room to outpatient care: after an overdose, a patient would be connected directly to buprenorphine treatment rather than left to navigate the next steps alone. The proposed approach included Sublocade, a newly FDA-approved once-monthly injection, as a means of making outpatient medication treatment part of that handoff.

The proposal addressed a recurring break in the care pathway. Emergency clinicians could revive a patient, but a referral did not itself ensure an appointment, access to medication, or continued care. In Roanoke, local psychologist Cheri Hartman and emergency physician Karen Kuehl were working toward a similar transfer from the hospital to outpatient medication-assisted treatment and counseling. They encountered bureaucratic, financial, and legal obstacles, along with too few medication providers and detoxification and treatment beds. Bickel’s pilot belonged to this wider effort to turn an emergency intervention into an organized route onward.

Evidence and treatment decisions

Bickel’s concern was not only whether treatment existed, but whether clinical practice used it in keeping with the evidence. He had recently lost a family friend who was taking Suboxone. After the patient tested positive for additional opioids at a follow-up visit, the doctor reduced the Suboxone dose as punishment. Bickel argued that the patient needed a higher dose, not a lower one. The example exposed the consequences of treating continued opioid use as a reason to withdraw medication rather than as a clinical signal within a difficult, ongoing illness.

When told that Tess Henry was homeless in Las Vegas and paying for illicit drugs through sex work, Bickel pointed to a study he had coauthored in 1988. The research showed that buprenorphine protects people with addiction from overdose death and is associated with reduced crime and better health. His response underlined the distance between evidence already available and treatment reaching people in practice: even a decades-old finding, he observed, remained unfamiliar to many. Tess’s circumstances are reported as a stark measure of that distance, not as evidence that she took part in the institute’s pilot.

Local capacity and the implementation gap

The proposed research unfolded against persistent limits on local treatment access. Roanoke’s community services board had recently added medication-assisted treatment for twenty-one patients, but required them to engage in counseling first. Outpatient medication treatment through the local hospital system still involved a three-week wait. At a forum sponsored by Carilion Clinic, a suggestion that doctors who had accepted Purdue Pharma promotional items should become authorized to prescribe Suboxone met with silence. These examples show why designing a referral protocol was only one part of the problem: treatment required available prescribers, workable entry routes, and institutions prepared to expand capacity.

The account therefore gives Virginia Tech Carilion Research Institute a specific, bounded significance. It is the setting for a pilot intended to connect overdose survival with continuing medication treatment, not a claim that research alone resolved the region’s shortages. The institute’s proposed bridge ran between two realities in the narrative: evidence that buprenorphine can reduce serious harm, and a fragmented system in which referrals, waits, eligibility conditions, and clinical decisions could still interrupt access.